Summary by Moomoo AI
BlackRock, Inc., a major investment management corporation based in Delaware, has filed a Schedule 13G with the Securities and Exchange Commission (SEC) on February 2, 2024, indicating a significant ownership stake in Cardio Diagnostics Holdings Inc. The filing reveals that BlackRock now beneficially owns 1,067,062 shares of common stock in Cardio Diagnostics Holdings, which represents 5.2% of the company's class of securities. This level of ownership classifies BlackRock as a parent holding company or control person under SEC rules. The filing was made in accordance with Rule 13d-1(b), and the shares are held in the ordinary course of business, not with the purpose of changing or influencing the control of the issuer. The date of the event which required the filing of this statement was December 31, 2023. Cardio Diagnostics Holdings Inc. is headquartered at 311 W. Superior Street, Suite 444, Chicago, IL 60645.